查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1189754

气道支架/肺支架市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Airway Stent/Lung Stent Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计气道/肺支架市场在预测期内的复合年增长率为 6.2%。

由于与 COVID-19 相关的呼吸窘迫增加，COVID-19 大流行对气道/肺支架市场产生了显着影响。 根据 2022 年 8 月发表在 PubMed 上的一篇论文，气管支气管支架术可以相对安全有效地治疗气管支气管狭窄。 在全身麻醉和气道正压下，通常使用硬质支气管镜放置硅胶支架。 与本研究一样，在静脉体外膜氧合 (VV-ECMO) 下，通过术中支气管支架置入术成功治疗了 COVID-19 患者肿瘤引起的支气管狭窄。 此外，2021 年 EHS 发表的一份病例报告显示，对于 COVID-19 患者，球囊扩张联合支架置入是替代再次手术的良好选择。 随着个性化患者专用气道支架的使用和其他医疗级材料的进一步进步，气道支架市场在未来几年可能会出现增长。

由于肺部和呼吸系统疾病的患病率上升以及人们对微创手术的偏好增加，预计气道/肺支架市场将呈现健康增长。 根据 Cancer Tomorrow 的报告，到 2025 年，预计肺癌患者人数将达到 2,519,283 人。 气道和肺支架手术也是微创手术。 这意味着更短的住院时间和更少的术后疼痛。 由于微创手术的简便性，世界各地的许多人更喜欢侵入性手术，这增加了市场价值。

根据 2022 年 4 月发表在《自然》杂誌上的一篇论文，在食管癌并发恶性气道狭窄的患者中，预先置入气道支架可减轻呼吸困难并需要额外的随访。已证明可提供治疗选择。 联合使用经动脉灌注化疗（TAIC）可以安全有效地治疗食管癌并发严重气道狭窄。 此外，与气道/肺支架相关的产品批准和研发正在推动市场增长。 例如，2020 年 1 月，美国 FDA 批准了克利夫兰诊所医生 Tom Gildea 开发的患者专用气道支架。

因此，考虑到上述因素，气道/肺支架市场在预测期内可能会出现增长。 然而，潜在的替代疗法和与支架相关的并发症正在抑制市场增长。

气道支架市场趋势

预测期内硅支架有望快速增长

硅胶支架可有效维持气道通畅，耐受性良好，几乎没有危及生命的并发症。 与其他材料製成的支架相比，硅胶支架安全、经济且易于操作。 硅胶支架有球囊扩张型和扩张型。 这些支架对患有良性和癌症相关气管支气管狭窄的患者非常有用。 硅胶支架部分在预测期内可能会出现增长。 硅胶支架是更好的选择，因为它们更容易移除并且不太可能损坏未来的程序。

此外，肺部和呼吸道疾病患病率的增加是市场增长的主要驱动力之一。 据 AAFA 称，到 2021 年将有大约 2500 万人患有哮喘病。 据同一消息来源称，2021 年约有 500 万美国年轻人患有哮喘病。 此外，硅胶支架可用于肺移植中的狭窄。 因此，在治疗过程中它们优于其他材料。

增加硅胶支架领域的研发将提高硅胶支架的采用潜力。 根据 2021 年 4 月发表在《自然》杂誌上的一篇论文，GINA 支架的一个关键特征是其灵活的动态结构，可以减小支架的横截面积。 由于 GINA 支架有一个扁平部分，就像实际气管支气管树的膜部一样，支架更容易收缩，增强的呼气流量有助于去除气道分泌物。

因此，考虑到上述因素，硅胶支架部分在预测期内可能会出现增长。

预测期内北美气道支架/肺支架市场有望增长

由于气道肺病的高患病率、先进的医疗保健系统以及支架等医疗设备的报销情况，北美可能会经历气道/肺支架市场的增长。 根据 Cancer.Net 2022 更新，到 2022 年，美国估计将有 236,740 名成年人（117,910 名男性和 118,830 名女性）被诊断出患有肺癌。 此外，根据 Asthma.ca 的 2021 年年度报告，每天都有 317 名加拿大人被新诊断出患有哮喘病。 报告称，在加拿大，哮喘是第三大常见慢性病，影响着超过 380 万加拿大人的生活。

此外，在整个地区开展了许多与气道支架相关的研究活动。 例如，根据 UMMC 的 2022 年报告，定制的 3D 支架为患者提供了更轻鬆的呼吸途径。 一名患者接受了 3D 打印硅胶支架的放置，该支架紧贴在裂隙中，裂隙将左主支气管分为左肺的上支气管和下支气管，将空气输送到患者的肺部。 日本大量的气道/肺支架製造公司是市场扩张的一个主要因素。 例如，2021 年 3 月，Alaxo Airway Stents（Alaxo）与加拿大阿尔伯塔省的波蒂奇学院合作，加强其在北美的影响力。

此外，政府和非政府组织不断努力也增加了总收入。 每年 11 月，AACR 和 ALA 都会庆祝肺癌宣传月。 通过该计划，该组织提供了对肺癌的批判性认识，并教育公众了解肺部健康的重要性。

因此，考虑到上述因素，北美很可能在预测期内出现增长。

气道支架市场竞争分析

气道支架市场是分散的，在几个国家有各种主要参与者和本地参与者。 各大企业纷纷采取併购、战略联盟等战略，以提高市场竞争力。 竞争格局包括对少数具有市场份额的知名国际和本地公司的分析。 主要竞争对手有波士顿科学公司、泰熊医疗、库克集团、微泰（南京）、美瑞医疗等。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 肺部和呼吸系统疾病患病率上升
    • 越来越喜欢微创手术
  • 市场製约因素
    • 替代疗法的可用性
    • 与支架相关的并发症
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品分类
    • 自扩张支架
    • 球囊扩张支架
  • 按材料
    • 金属
      • 镍钛诺
      • 不銹钢
    • 硅胶
    • 混合型
  • 按类型
    • 气管/支气管支架
    • 喉支架
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Bess medizintechnik GmbH
    • Boston Scientific Corporation
    • Cook Group
    • E. Benson Hood Laboratories Inc.
    • Efer Endoscopy
    • Endo-Flex GmbH
    • Merit Medical Systems Inc.
    • Micro-Tech（Nanjing）Co. Ltd
    • Standard Sci Tech Inc.
    • Taewoong Medical Co. Ltd

第7章 市场机会今后动向

简介目录
Product Code: 67340

The airway stent /lung stent market is expected to register a CAGR of 6.2% during the forecast period.

The COVID-19 pandemic had a notable impact on the airway stent /lung stent market due to the increase in respiratory difficulties associated with COVID-19. According to an article published in PubMed in August 2022, tracheobronchial stenosis can be treated relatively safely and effectively with tracheobronchial stent insertion. Under general anesthesia and positive pressure breathing, rigid bronchoscopy is commonly used to place silicone stents. As per the study, the treatment of tracheobronchial stenosis brought on by a tumor in a patient with COVID-19 was successfully managed intraoperatively by tracheobronchial stenting under venovenous extracorporeal membrane oxygenation (VV-ECMO). Furthermore, a case report published in 2021 by EHS showed that the combination of balloon dilatation and stent implantation is a good alternative to reoperation for patients with COVID-19. Due to the availability of individualized airway stents for each patient and other additional medical-grade materials advancements, the airway stent market is likely to witness growth in the coming years.

The airway stent /lung stent market is expected to witness healthy growth due to the rising prevalence of lung and respiratory disorders and people's growing preference for minimally invasive surgeries. As per the Cancer Tomorrow report, the estimated number of lung cancer cases is projected to be 2,519,283 by 2025. In addition, surgery with the airway or lung stent is minimally invasive. This means there is a lesser hospital stay and minimal pain generated post-surgery. Many people are preferring invasive surgeries around the globe due to the ease of minimally invasive surgeries, which adds value to the market.

As per the article published in April 2022 by Nature journal, the study showed that airway stents could be inserted first to reduce dyspnea intolerance in patients with esophageal cancer complicated by malignant airway stenosis and provide options for additional follow-up treatment. Sequential treatment of esophageal cancer complicated by severe airway stenosis is safe and effective when used with transarterial infusion chemotherapy (TAIC). Furthermore, product approvals and R&D relating to the airway stent/lung stent are boosting the market growth. For instance, in January 2020, the US FDA cleared patient-specific airway stents developed by Cleveland Clinic physician Tom Gildea.

Hence considering the above-mentioned factors, the airway stent /lung stent market is likely to witness growth during the forecast period. However, the availability of alternative treatments and complications associated with stents restrain the market growth.

Airway Stent Market Trends

Silicon Stents are Expected to Witness Rapid Growth During the Forecast Period

Silicon stents are effective in maintaining airway patency and are associated with good tolerance and infrequent complications that are rarely life-threatening. They are safe, cost-effective, and easy to manipulate compared to other stents with different materials. The silicon stents come in balloon-expandable and expandable versions. These stents have been very useful in patients suffering from benign and cancer-related tracheobronchial strictures. The silicon stent segment is likely to witness growth during the forecast period. Silicone stents are better options as they are simpler to remove and are less likely to damage a future procedure.

Furthermore, the increasing prevalence of lung and airway disease is one of the major driving factors for market growth. According to AAFA, approximately 25 million people had asthma in 2021. According to the same source, around 5 million American youngsters had asthma in 2021. Additionally, silicon stents are also useful in lung transplantation strictures. Thus they are preferred over other materials during the treatment.

Increased R&D in the field of silicon stents improves the chances of adoption of silicon stents. As per the article published in April 2021 by Nature journal, an important feature of the GINA stent is the flexible, dynamic structure, which enables the reduction of the stent's cross-sectional area. The GINA stent has a flat part, like the membranous portion of the actual tracheobronchial tree, which makes the stent more contractible and facilitates the removal of airway secretions through an enhanced expiratory flow.

Hence, considering the above-mentioned factors, the silicon stents segment is likely to witness growth during the forecast period.

North America is Expected to Witness a Growth in the Airway Stent/Lung Stent Market During the Forecast Period

North America is likely to experience growth in the airway stent/lung stent market due to the high prevalence of airway-lung diseases, the developed healthcare system, and the reimbursement scenario for medical devices such as stents. As per the Cancer.Net 2022 update, an estimated 236,740 adults (117,910 men and 118,830 women) in United States are likely to be diagnosed with lung cancer in 2022. Furthermore, according to the Asthma.ca 2021 annual report, every day, 317 Canadians are newly diagnosed with asthma. As per the same source, across Canada, asthma affects the lives of more than 3.8 million Canadians and is the third most common chronic disease.

In addition, many research activities are carried out relating to airway stents across the region. For instance, as per the 2022 report from the UMMC, custom-fitted 3D stent gives patients a route to easier breathing. A patient received placement of a silicone stent, made on a 3D printer, that sits snugly in the split that divides the left main bronchus to the upper and lower bronchi of the left lung that carry air to the patient's lungs. The presence of many companies that manufacture airway/lung stents in the country is a significant factor responsible for the large market size. For instance, in March 2021, Alaxo Airway Stents (Alaxo) strengthened its presence in North America by partnering with Portage College in Alberta, Canada.

Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. Every November, the AACR and ALA celebrate Lung Cancer Awareness Month. Through the program, the organizations provide critical awareness about lung cancer and educate the public regarding the importance of lung health.

Hence considering the above-mentioned factors, North America is likely to witness growth during the forecast period.

Airway Stent Market Competitive Analysis

The market for airway stents is fragmented, with different key players and a few local companies in several countries. The major companies have adopted strategies like mergers and acquisitions and strategic alliances to gain a competitive advantage in the market. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Major competitors are Boston Scientific Corporation, Taewoong Medical Co. Ltd, Cook Group, Micro-Tech (Nanjing) Co. Ltd, and Merit Medical Systems Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Lung and Rspiratory Disorders
    • 4.2.2 Growing Preference of People For Minimally Invasive Surgeries
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Complications Associated with Stents
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Self-Expandable Stents
    • 5.1.2 Balloon- Expandable Stents
  • 5.2 By Material
    • 5.2.1 Metal
      • 5.2.1.1 Nitinol
      • 5.2.1.2 Stainless Steel
    • 5.2.2 Silicone
    • 5.2.3 Hybrid
  • 5.3 By Type
    • 5.3.1 Tracheobronchial Stents
    • 5.3.2 Laryngeal Stents
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bess medizintechnik GmbH
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Cook Group
    • 6.1.4 E. Benson Hood Laboratories Inc.
    • 6.1.5 Efer Endoscopy
    • 6.1.6 Endo-Flex GmbH
    • 6.1.7 Merit Medical Systems Inc.
    • 6.1.8 Micro-Tech (Nanjing) Co. Ltd
    • 6.1.9 Standard Sci Tech Inc.
    • 6.1.10 Taewoong Medical Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS